BioWorld

Aug. 30, 2010

Genentech Caught off Guard, FDA Issues Refuse-to-File for T-DM1

The FDA sent a refuse-to-file letter to Genentech Inc., a member of the Roche Group, rejecting the company's application for accelerated approval of trastuzumab-DM1 (T-DM1) and catching investors and the company off guard. (BioWorld Today) Read More

Otonomy Lures New Investors with $38.5M Series B Financing

Senate to Hold Hearing on Funding for Stem Cells

FDA Oversteps its Bounds for Jazz Fibromyalgia Drug

Genzyme's ERT Rationing to End Soon; Sanofi Still Biting?

Corrections & Clarifications

Clinic Roundup

Stock Movers

Financings Roundup

Other News To Note

U.S. Patent Disclosures

Bench Press

Today's news in brief

BioWorld

BioWorld briefs for April 23, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 21, 2026

Psychedelic space expanding on Trump’s EO

BioWorld

Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...

At AACR: Epigenetic fingerprints in metastases track tumor origin

BioWorld

When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...

In the clinic for April 21, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...